The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Expert Addresses Major Challenge in Treatment of Myeloma

David M. Siegel, MD, PhD
Published Online:5:14 PM, Tue January 8, 2019

David S. Siegel, MD, PhD, chief of the division of multiple myeloma at John Theurer Cancer Center, Hackensack Meridian Health, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.

According to Siegel, there is a notion that it is imperative to change classes of drugs when there is progression of disease. This is believed by both community oncologists and myeloma experts alike.

This often results in a change from bortezomib (Velcade) to carfilzomib (Kyprolis) or lenalidomide (Revlimid) to pomalidomide (Pomalyst). However, Siegel says the question is if this is really true, and if so, for which drugs?
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.